By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


PharmaMar S.A. 

Pol Ind. la Mina Avenida de los Reyes, 1

Colmenar Viejo  Madrid  28770  Spain
Phone: 34-91-8466000 Fax: 34-91-8466001


Company News
PharmaMar Submits MAA To EMA For Aplidin For The Treatment Of Multiple Myeloma 9/22/2016 8:16:45 AM
PharmaMar Announces The IDMC´s Response On The CORAIL Trial Using PM1183 8/11/2016 12:14:46 PM
PharmaMar S.A. Initiates A Pivotal Phase III ATLANTIS Study With PM1183 In Combination With Doxorubicin In Patients With Small Cell Lung Cancer 8/2/2016 7:24:27 AM
PharmaMar S.A. Announces The Start Of A Pivotal Study With Plitidepsin In Angioimmunoblastic T-Cell Lymphoma 6/15/2016 11:08:45 AM
PharmaMar S.A. Release: The Phase III Clinical Trial Using PM1183 In Treating Ovarian Cancer (CORAIL) Continues Following The IDMC's Positive Recommendation 2/8/2016 8:53:06 AM
PharmaMar S.A. And Specialised Therapeutics Asia Sign Licensing And Marketing Agreement For APLIDIN (plitidepsin) Covering Several Asian Countries 2/2/2016 7:45:44 AM
PharmaMar S.A. Sets Up Unit In London 9/15/2015 11:56:10 AM
PharmaMar S.A. Announces License Agreement With TTY Biopharm For APLIDIN (plitidepsin) In Hematological Cancers 7/23/2015 7:55:20 AM
PharmaMar S.A. Initiates The Phase III Study CORAIL For The Anticancer Agent PM1183 In Patients With Platinum-Resistant Ovarian Cancer 6/29/2015 6:20:27 AM
Myriad Genetics, Inc. (MYGN) Partners With PharmaMar S.A. for New HRD Test 3/29/2013 8:23:55 AM